---
title: 'Nivolumab combination therapies in patients with advanced gastric and gastroesophageal
  junction cancer: the phase II FRACTION gastric cancer study'
date: '2025-01-11'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39798422/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250112170448&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: While ORR did not meet prespecified expansion criteria
  in any treatment arm, the safety profile of the combinations was manageable. FRACTION-GC
  represents a novel adaptive protocol for testing multiple combination ...'
disable_comments: true
---
CONCLUSIONS: While ORR did not meet prespecified expansion criteria in any treatment arm, the safety profile of the combinations was manageable. FRACTION-GC represents a novel adaptive protocol for testing multiple combination ...